

PATENT/Docket No. PC9868D

Serial No. 10/825,406

Page 3

Response to Final 04/01/2005 OA


Amendment to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

Claims 1-27. (Cancelled)

28. (New) A compound of the formula



or the pharmaceutically acceptable salt thereof;

wherein a is 1;

V is CHR^{10} wherein R^{10} is hydrogen or $(\text{C}_1\text{-C}_6)\text{alkyl}$;

T is nitrogen or CH;

X is nitrogen;

Y and Z are each independently nitrogen or CR^{12} , wherein R^{12} is hydrogen, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, $(\text{C}_1\text{-C}_6)\text{alkoxy}$ or $(\text{C}_1\text{-C}_6)\text{alkyl}$, provided that at least one of T, Y, and Z is nitrogen;

R^1 is hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano or $(\text{C}_1\text{-C}_6)\text{alkyl}$;

R^2 , R^6 , R^7 , R^8 and R^9 are each independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, $(\text{C}_1\text{-C}_6)\text{alkoxy}$ and $(\text{C}_1\text{-C}_6)\text{alkyl}$;

R^3 and R^4 are each independently hydrogen or $(\text{C}_1\text{-C}_6)\text{alkyl}$; and

R^5 is hydrogen, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, trifluoromethyl, cyano, $(\text{C}_1\text{-C}_6)\text{alkyl}$ or $\text{R}^{13}\text{CO-}$ wherein R^{13} is amino, $(\text{C}_1\text{-C}_6)\text{alkylamino}$, $((\text{C}_1\text{-C}_6)\text{alkyl})_2\text{amino}$, $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}$.

29. (New) A compound according to claim 28, wherein Y and Z are each CR^{12} wherein R^{12} is hydrogen or fluoro.

30. (New) A compound according to claim 28, wherein R^2 is hydrogen, fluoro or chloro.

31. (New) A compound according to claim 28, wherein R^3 , R^4 and R^5 are hydrogen.

FORM PTORSP
Rev. 5/1/03

PATENT/Docket No. PC9868D

Serial No. 10/825,406

Page 4

Response to Final 04/01/2005 OA

32. (New) A compound according to claim 28, wherein R⁷ is fluoro or chloro.
33. (New) A compound according to claim 28, wherein R⁹ is fluoro, chloro, bromo or alkoxy.
34. (New) A compound according to claim 28, wherein X is nitrogen; Y and Z are each CR¹² wherein R¹² is hydrogen or fluoro; R² is hydrogen fluoro or chloro; R³, R⁴ and R⁵ are hydrogen; R⁷ is fluoro or chloro; and R⁷ is fluoro, chloro, bromo or alkoxy.
35. (New) A compound according to claim 28, wherein said compound is selected from the group consisting of:
- 5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
 - 2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-ylmethyl]-5-fluoro-1H-indole;
 - 5-Fluoro-2-(4-[5'-fluoro]pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
 - 2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
 - 5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole; and
 - 5-Fluoro-2-(4-pyrimidin-2-yl-piperazin-1-ylmethyl)-1H-indole.
36. (New) A method for treating a disorder of the dopamine system in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to claim 28, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder.
37. (New) A method according to claim 36, wherein disorders of the dopamine system include psychotic disorders, movement disorders, gastrointestinal disorders, chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders, ocular disorders and sleep disorders.
38. (New) A method for treating a disorder of the dopamine system in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to claim 28, or a pharmaceutically acceptable salt thereof, in conjunction with one or more D1, D2, D3 or D5 dopamine receptor agonists, that is effective in treating such disorder.
39. (New) A method according to claim 38, wherein disorders of the dopamine system include psychotic disorders, movement disorders, gastrointestinal disorders, chemical abuse, chemical

FORM PTORSP
Rev. 5/1/03

PATENT/Docket No. PC9868D

Serial No. 10/825,406

Page 5

Response to Final 04/01/2005 OA

dependencies, substance abuse, vascular and cardiovascular disorders, ocular disorders and sleep disorders.

40. (New) A method according to claim 37, wherein psychotic disorders include affective psychosis, schizophrenia, and schizoaffective disorders.

41. (New) A method according to claim 37, wherein movement disorders include extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La Tourette's syndrome, Parkinson's disease or Huntington's disease.

42. (New) A method according to claim 37, wherein gastrointestinal disorders include gastric acid secretion or emesis.

43. (New) A method according to claim 37, wherein vascular and cardiovascular disorders include congestive heart failure and hypertension.

FORM PTORSP
Rev. 5/1/03